•  Today I will take
  • my stem cells to the bank.
  • Thomas Fowell (38), Asset Manager
  •  I'm glad there is a bank
  • where I can invest
  • my health profitably.
  • Michelle Li (35), Sales Manager Beauty/Kosmetik
  •  I have put aside something
  • for the future: my stem cells
  • Sammo Yeng (39), CEO

TICEBA is a highly innovative German bio-pharmaceutical Life-Science Company, which operates in the fields of stem cell research and regenerative medicine. As the world's first private tissue bank, the German company offers its clients the removal and storage of the cells from the skin and the stem cells contained therein as personal, biological life insurance and has established itself as a pharmaceutical active ingredient manufacturer for stem cell-based therapies.


TICEBA Creation of a unique biological life insurance
Production: July 2014


TICEBA corporate video Back-up Your Life!
Production: September 2011

News
Article about our study with limbal stem cells

On the website of the Harvard Stem Cell Institute you will find the following news release about the ongoing clinical trial conducted by our daughter company RHEACELL in patients suffering from limbal stem cell deficiency: Restoring vision: A stem cell therapy for cornea regeneration reaches the clinical-trial stage.

Clinical Trial - EB

The international phase I/IIa clinical trial has been approved by the U.S. Food and Drug Administration (FDA) and several European competent national regulatory authorities. The medicinal drug product tested in this trial has recently been granted Orphan Drug designation from the FDA and the European Medicines Agency (EMA) for the treatment of EB.

Clinical Trial - LSCD

The international phase I/IIa clinical trial has been approved by the U.S. Food and Drug Administration (FDA) and the German regulatory authority (Paul Ehrlich Institute). The medicinal drug product tested in this trial has recently been granted Orphan Drug designation from the FDA and the European Medicines Agency (EMA) and Fast Track designation from the FDA for the treatment of LSCD.

Safety

In a comprehensive preclinical study program, safety and local tolerability of ABCB5+ MSCs following subcutaneous, intramuscular and intravenous application has been demonstrated (Tappenbeck et al., 2019).

Newsletter